GlaxoSmithKline buys US partner in $3bn deal

GlaxoSmithKline boosted its pipeline of drugs today with a $3bn (€2.44bn) deal for its American partner on a potential blockbuster medicine.
The proposed acquisition of Human Genome Sciences (HGS) means it has secured the full rights for Benlysta, the first new drug to be approved to treat immune system disease lupus in the US for more than 50 years.